gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Prediction of response to chemotherapy using 18-fluorodeoxyglucose positron emission tomography in advanced oesophageal and gastric cancer

Meeting Abstract

  • corresponding author presenting/speaker Sylvie Lorenzen - 3rd Department of Internal Medicine (Haematology/Medical Oncology), Klinikum rechts der Isar, Technical University of Munich, München, Deutschland
  • Ken Herrmann - Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich
  • Hinrich Wieder - Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich
  • Michael Hennig - Institute for Medical Statistics and Epidemiology, Technical University of Munich
  • Rainer Bredenkamp - Munich Center for Clinical Studies, Klinikum rechts der Isar
  • Christian Peschel - 3rd Department of Internal Medicine (Haematology/Medical Oncology), Klinikum rechts der Isar, Technical University of Munich
  • Michael Schwaiger - Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich
  • Florian Lordick - 3rd Department of Internal Medicine (Haematology/Medical Oncology), Klinikum rechts der Isar, Technical University of Munich

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO202

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk312.shtml

Veröffentlicht: 20. März 2006

© 2006 Lorenzen et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

This study was carried through to assess the value of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) for the early metabolic response assessment in oesophago-gastric cancer. 26 patients who were treated for advanced disease (18 adenocarcinomas, 6 squamous-cell cancers) underwent FDG-PET before and two weeks after the onset of chemotherapy with either oxaliplatin-fluorouracil-folinic acid or with docetaxel-capecitabine. 24 tumours (92%) could be visualised by FDG-PET and were also assessable by a second PET 2 weeks after the start of chemotherapy. Receiver Operating Characteristic (ROC) analysis revealed a 30% decrease of the standard uptake value (SUV) as most accurate and clinically meaningful in predicting response according to RECIST. Applying this 30% cut off value, PET imaging correctly predicted clinical response with a sensitivity of 73% and a specificity of 50% (60% and 33% in gastric cancer compared to 100% and 60% in oesophageal cancer). Median time to progression and overall survival were not significantly different for metabolic responders and nonresponders (6.3 versus 5.3 months and 14.1 versus 12.5 months, respectively). Data indicate that FDG-PET is inaccurate for the prediction of response in gastric cancer. In contrast, the method is promising in advanced oesophageal cancer and merits further investigation.